CN105412227A - Unsaturated fatty acid dietary supplement and preparing method thereof - Google Patents
Unsaturated fatty acid dietary supplement and preparing method thereof Download PDFInfo
- Publication number
- CN105412227A CN105412227A CN201510873194.0A CN201510873194A CN105412227A CN 105412227 A CN105412227 A CN 105412227A CN 201510873194 A CN201510873194 A CN 201510873194A CN 105412227 A CN105412227 A CN 105412227A
- Authority
- CN
- China
- Prior art keywords
- fatty acid
- unsaturated fatty
- dietary supplement
- soft capsule
- oil
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 235000021122 unsaturated fatty acids Nutrition 0.000 title claims abstract description 41
- 150000004670 unsaturated fatty acids Chemical class 0.000 title claims abstract description 41
- 235000015872 dietary supplement Nutrition 0.000 title claims abstract description 28
- 238000000034 method Methods 0.000 title claims abstract description 13
- 229940106134 krill oil Drugs 0.000 claims abstract description 25
- 235000021323 fish oil Nutrition 0.000 claims abstract description 24
- 239000003292 glue Substances 0.000 claims abstract description 23
- 235000001498 Salvia hispanica Nutrition 0.000 claims abstract description 21
- 238000001035 drying Methods 0.000 claims abstract description 11
- 235000019198 oils Nutrition 0.000 claims abstract description 8
- 239000007901 soft capsule Substances 0.000 claims description 45
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 39
- 108010010803 Gelatin Proteins 0.000 claims description 23
- 229920000159 gelatin Polymers 0.000 claims description 23
- 239000008273 gelatin Substances 0.000 claims description 23
- 235000019322 gelatine Nutrition 0.000 claims description 23
- 235000011852 gelatine desserts Nutrition 0.000 claims description 23
- 240000005481 Salvia hispanica Species 0.000 claims description 20
- 239000000463 material Substances 0.000 claims description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 17
- 238000002360 preparation method Methods 0.000 claims description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 14
- 235000015112 vegetable and seed oil Nutrition 0.000 claims description 14
- 239000000203 mixture Substances 0.000 claims description 11
- 239000002994 raw material Substances 0.000 claims description 9
- 238000004140 cleaning Methods 0.000 claims description 8
- 239000002552 dosage form Substances 0.000 claims description 5
- 238000005213 imbibition Methods 0.000 claims description 5
- 238000002156 mixing Methods 0.000 claims description 5
- 230000008569 process Effects 0.000 claims description 5
- 238000002791 soaking Methods 0.000 claims description 5
- 238000003756 stirring Methods 0.000 claims description 5
- 238000001914 filtration Methods 0.000 claims description 3
- 230000000694 effects Effects 0.000 abstract description 18
- 230000001976 improved effect Effects 0.000 abstract description 4
- 239000013589 supplement Substances 0.000 abstract description 4
- 239000004615 ingredient Substances 0.000 abstract description 2
- 244000292604 Salvia columbariae Species 0.000 abstract 1
- 235000012377 Salvia columbariae var. columbariae Nutrition 0.000 abstract 1
- 235000014167 chia Nutrition 0.000 abstract 1
- 239000012467 final product Substances 0.000 abstract 1
- 239000006187 pill Substances 0.000 abstract 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 34
- 210000004369 blood Anatomy 0.000 description 24
- 239000008280 blood Substances 0.000 description 24
- 241001465754 Metazoa Species 0.000 description 16
- DVSZKTAMJJTWFG-UHFFFAOYSA-N docosa-2,4,6,8,10,12-hexaenoic acid Chemical compound CCCCCCCCCC=CC=CC=CC=CC=CC=CC(O)=O DVSZKTAMJJTWFG-UHFFFAOYSA-N 0.000 description 16
- MBMBGCFOFBJSGT-KUBAVDMBSA-N docosahexaenoic acid Natural products CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 description 16
- 208000024891 symptom Diseases 0.000 description 15
- 238000012360 testing method Methods 0.000 description 14
- 235000012000 cholesterol Nutrition 0.000 description 13
- 230000002265 prevention Effects 0.000 description 12
- 208000031226 Hyperlipidaemia Diseases 0.000 description 11
- 230000037396 body weight Effects 0.000 description 11
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 235000020673 eicosapentaenoic acid Nutrition 0.000 description 10
- 229960005135 eicosapentaenoic acid Drugs 0.000 description 10
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 description 10
- 239000000194 fatty acid Substances 0.000 description 10
- 235000013305 food Nutrition 0.000 description 10
- 150000002632 lipids Chemical class 0.000 description 10
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 10
- 201000010099 disease Diseases 0.000 description 9
- 150000003626 triacylglycerols Chemical class 0.000 description 9
- 241000700159 Rattus Species 0.000 description 8
- 235000014113 dietary fatty acids Nutrition 0.000 description 8
- 239000003925 fat Substances 0.000 description 8
- 235000019197 fats Nutrition 0.000 description 8
- 229930195729 fatty acid Natural products 0.000 description 8
- 150000004665 fatty acids Chemical class 0.000 description 8
- 238000003304 gavage Methods 0.000 description 8
- 210000002216 heart Anatomy 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 7
- 108010010234 HDL Lipoproteins Proteins 0.000 description 7
- 102000015779 HDL Lipoproteins Human genes 0.000 description 7
- 208000006011 Stroke Diseases 0.000 description 7
- 229910052799 carbon Inorganic materials 0.000 description 7
- 230000008859 change Effects 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 7
- 206010008190 Cerebrovascular accident Diseases 0.000 description 6
- 108010023302 HDL Cholesterol Proteins 0.000 description 6
- 208000007536 Thrombosis Diseases 0.000 description 6
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 6
- 210000004204 blood vessel Anatomy 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 239000003921 oil Substances 0.000 description 6
- 239000008213 purified water Substances 0.000 description 6
- 208000011775 arteriosclerosis disease Diseases 0.000 description 5
- 210000000038 chest Anatomy 0.000 description 5
- 230000003203 everyday effect Effects 0.000 description 5
- 230000004438 eyesight Effects 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 238000004513 sizing Methods 0.000 description 5
- 206010008132 Cerebral thrombosis Diseases 0.000 description 4
- 206010020772 Hypertension Diseases 0.000 description 4
- 201000001429 Intracranial Thrombosis Diseases 0.000 description 4
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 230000036772 blood pressure Effects 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 208000029078 coronary artery disease Diseases 0.000 description 4
- 235000005911 diet Nutrition 0.000 description 4
- 230000037213 diet Effects 0.000 description 4
- 210000003743 erythrocyte Anatomy 0.000 description 4
- 235000004626 essential fatty acids Nutrition 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 235000016709 nutrition Nutrition 0.000 description 4
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 4
- 210000001525 retina Anatomy 0.000 description 4
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 3
- 241000239366 Euphausiacea Species 0.000 description 3
- 108010007622 LDL Lipoproteins Proteins 0.000 description 3
- 102000007330 LDL Lipoproteins Human genes 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 206010067482 No adverse event Diseases 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- 230000003187 abdominal effect Effects 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 231100000460 acute oral toxicity Toxicity 0.000 description 3
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 3
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 210000004958 brain cell Anatomy 0.000 description 3
- 239000004202 carbamide Substances 0.000 description 3
- 235000013877 carbamide Nutrition 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 208000026106 cerebrovascular disease Diseases 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 230000000857 drug effect Effects 0.000 description 3
- 238000002594 fluoroscopy Methods 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 229960004488 linolenic acid Drugs 0.000 description 3
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 230000001502 supplementing effect Effects 0.000 description 3
- 238000002604 ultrasonography Methods 0.000 description 3
- 108010088751 Albumins Proteins 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- 206010003210 Arteriosclerosis Diseases 0.000 description 2
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 2
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 102000001554 Hemoglobins Human genes 0.000 description 2
- 108010054147 Hemoglobins Proteins 0.000 description 2
- 206010061216 Infarction Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 229930010555 Inosine Natural products 0.000 description 2
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 2
- 238000012449 Kunming mouse Methods 0.000 description 2
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 208000005374 Poisoning Diseases 0.000 description 2
- 101710098398 Probable alanine aminotransferase, mitochondrial Proteins 0.000 description 2
- 206010039966 Senile dementia Diseases 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 235000021342 arachidonic acid Nutrition 0.000 description 2
- 229940114079 arachidonic acid Drugs 0.000 description 2
- 230000002917 arthritic effect Effects 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000023555 blood coagulation Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 235000013339 cereals Nutrition 0.000 description 2
- 206010008118 cerebral infarction Diseases 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 230000013872 defecation Effects 0.000 description 2
- 230000035614 depigmentation Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 230000002124 endocrine Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000002519 immonomodulatory effect Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000007574 infarction Effects 0.000 description 2
- 229960003786 inosine Drugs 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 235000020778 linoleic acid Nutrition 0.000 description 2
- 229960004232 linoleic acid Drugs 0.000 description 2
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 2
- 230000001050 lubricating effect Effects 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 235000021281 monounsaturated fatty acids Nutrition 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 231100000572 poisoning Toxicity 0.000 description 2
- 230000000607 poisoning effect Effects 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 210000002027 skeletal muscle Anatomy 0.000 description 2
- 230000007958 sleep Effects 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 238000002562 urinalysis Methods 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 235000019737 Animal fat Nutrition 0.000 description 1
- 108010071619 Apolipoproteins Proteins 0.000 description 1
- 102000007592 Apolipoproteins Human genes 0.000 description 1
- 206010003178 Arterial thrombosis Diseases 0.000 description 1
- 206010003211 Arteriosclerosis coronary artery Diseases 0.000 description 1
- JEBFVOLFMLUKLF-IFPLVEIFSA-N Astaxanthin Natural products CC(=C/C=C/C(=C/C=C/C1=C(C)C(=O)C(O)CC1(C)C)/C)C=CC=C(/C)C=CC=C(/C)C=CC2=C(C)C(=O)C(O)CC2(C)C JEBFVOLFMLUKLF-IFPLVEIFSA-N 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 108010074051 C-Reactive Protein Proteins 0.000 description 1
- 102100032752 C-reactive protein Human genes 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 206010010144 Completed suicide Diseases 0.000 description 1
- 241000238557 Decapoda Species 0.000 description 1
- 208000032928 Dyslipidaemia Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000005577 Gastroenteritis Diseases 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 235000008418 Hedeoma Nutrition 0.000 description 1
- 244000134716 Hodgsonia macrocarpa Species 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 240000007509 Phytolacca dioica Species 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 241000282894 Sus scrofa domesticus Species 0.000 description 1
- 206010047163 Vasospasm Diseases 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000002052 anaphylactic effect Effects 0.000 description 1
- 230000001194 anti-hemostatic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000002402 anti-lipaemic effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 235000013793 astaxanthin Nutrition 0.000 description 1
- MQZIGYBFDRPAKN-ZWAPEEGVSA-N astaxanthin Chemical compound C([C@H](O)C(=O)C=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)[C@@H](O)CC1(C)C MQZIGYBFDRPAKN-ZWAPEEGVSA-N 0.000 description 1
- 229940022405 astaxanthin Drugs 0.000 description 1
- 239000001168 astaxanthin Substances 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 235000020235 chia seed Nutrition 0.000 description 1
- 229940099352 cholate Drugs 0.000 description 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 208000026758 coronary atherosclerosis Diseases 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 238000004134 energy conservation Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 230000007407 health benefit Effects 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 230000002607 hemopoietic effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000014593 oils and fats Nutrition 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 210000001328 optic nerve Anatomy 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 235000021395 porridge Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 108700022737 rat Fat1 Proteins 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 235000015067 sauces Nutrition 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 208000029257 vision disease Diseases 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/612—Crustaceans, e.g. crabs, lobsters, shrimps, krill or crayfish; Barnacles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/60—Fish, e.g. seahorses; Fish eggs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
- A61K9/4825—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Marine Sciences & Fisheries (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Insects & Arthropods (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The embodiment of the invention discloses an unsaturated fatty acid dietary supplement. The unsaturated fatty acid dietary supplement is mainly prepared from 5-30 parts of krill oil, 30-100 parts of fish oil and 5-20 parts of chia oil. The invention provides a preparing method for the unsaturated fatty acid dietary supplement. The preparing method comprises the steps of glue liquor preparing, pill pressing, setting, drying and final product obtaining in sequence. According to the unsaturated fatty acid dietary supplement, the three effective ingredients supplement one another, the effect of unsaturated fatty acid is given into full play, the unsaturated fatty acid is well absorbed by the human body, and the efficacy is improved. The preparing method is easy to operate, convenient, safe, efficient and suitable for industrialized popularization, and saves energy.
Description
Technical field
The present invention relates to field of health care products, particularly relate to a kind of unsaturated fatty acid dietary supplement and preparation method thereof.
Background technology
Fatty acid is the important composition of composition fat, and its chemical constitution is with the long-chain main body of carbon composition.The structure connected between carbon and carbon claims key, is connected the title satisfied fatty acid being a key in fatty acid between carbon with carbon.All satisfied fatty acid, can naturally synthesize in human body, do not need from food supplementary especially.If be doubly linked between carbon and carbon, then claim unsaturated fatty acid.The condition of synthesis unsaturated fatty acid is not possessed in human body, should by food supply, therefore unsaturated fatty acid is also referred to as essential fatty acid.
Unsaturated fatty acid is a kind of fatty acid forming body fat, the indispensable fatty acid of human body.Unsaturated fatty acid, according to the difference of double bond number, is divided into monounsaturated fatty acid and polyunsaturated fatty acid two kinds.In food fat, monounsaturated fatty acid has oleic acid etc., and polyunsaturated fatty acid has linoleic acid, linolenic acid, arachidonic acid etc.Human body can not synthesize linoleic acid plus linolenic acid, must supplement from meals.Again polyunsaturated fatty acid is divided into ω-6 series and ω-3 series according to the position of double bond and function, linoleic acid and arachidonic acid belong to ω-6 series, and linolenic acid, that DHA, EPA belong to ω-3 is serial.
After deliberation, unsaturated fatty acid has good effect to various diseases, as it can adjusting blood lipid, cleaning thrombosis, immunomodulating, safeguard that retina improves vision, supplementing the brain brain-strengthening, improves arthritic symptom, eases the pain.Although also there are the nutrient and healthcare products being much rich in unsaturated fatty acid in the market, these products have plenty of nutritional labeling and arrange in pairs or groups unreasonable, and some drug effects are difficult to give full play to, and general effect is bad.
Summary of the invention
Embodiments provide a kind of unsaturated fatty acid dietary supplement, to solve the problem that unreasonable, the drug effect of unsaturated fatty acids nutrient and healthcare products nutritional labeling collocation existed in the market is difficult to give full play to.
In order to solve the problem, the embodiment of the invention discloses a kind of unsaturated fatty acid dietary supplement, being prepared from primarily of following raw material: krill oil 5 ~ 30 parts, 30 ~ 100 parts, fish oil, Salvia Hispanica L. seed oil 5 ~ 20 parts.
Alternatively, described dietary supplement dosage form is soft capsule.
Alternatively, also comprise gelatin 20-25 and divide, glycerol 8-12 divides, and water 20-25 divides.。
Above-mentioned krill oil can adopt a commercially available krill oil, can be also raw material by krill section krill, and through washing, fragmentation, extraction, concentrated, filtration step is obtained.
Raw material is introduced:
Krill is the biology the highest containing protein that people have been found that today, protein content reaches more than 50 percent, but also containing the very abundant necessary aminoacid of tissue and vitamin A, that the Nature is presented to the natural health food of the mankind, containing the irreplaceable effect of other food.Krill oil contains ω-3 essential fatty acid eicosapentaenoic acid (EPA) and docosahexenoic acid (DHA).ω-3 essential fatty acid has a lot of sanatory benefit, comprises cardiovascular, neural, skeleton and joint, vision, skin care etc.
Krill oil can reduce cholesterol, prevention cerebral hemorrhage, cerebral thrombosis, reduction blood viscosity, blood circulation promoting, prophylaxis of hypertension, nourishing the brain and improving intelligence, active thinking, prevention senile dementia.U.S. clinical confirms, krill oil has effect of superpower blood fat reducing, blood sugar lowering and blood pressure lowering, and can pass through blood brain barrier, and nutrition and activation brain cell and nerve, play the effect of prevention and therapy cerebrovascular disease; Meanwhile, prevention and therapy coronary atherosclerosis, coronary heart disease, there is the cardiovascular disease such as heart infarction in prevention; Certainly, krill oil can also play anti-inflammation, the developing of prophylaxis of cancer, the multi-efficiency such as slow down aging, endocrine regulation.
In addition, krill oil also has good effect to following disease:
(1) coronary heart diseases and angina pectoris, heart infarction, arteriosclerosis
Omega-3 unsaturated fatty acid abundant in krill oil effectively can be removed blood fat, vessel softening wall, significantly reduce LDL " bad " cholesterol in blood and triglyceride mass, promote HDL " optimum " cholesterol amount simultaneously, make blood vessel become more unblocked, more healthy and more flexible, this will lower the risk of heart attack or apoplexy significantly.Astaxanthin contained by it and animal-type flavonoid, can alleviate the oxidation of apolipoprotein, and to vascularization anti-oxidation protection, anti-hemostatic tube becomes fragile, hardens, and keeps blood vessel elasticity, can available protecting heart, prevention of arterial sclerosis and ischemic brain injury.Especially to medicated porridge sample arteriosclerosis and coronary heart disease, krill oil can obviously reduce c reactive protein level, greatly reduces sickness rate.
(2) hyperlipidemia, hyperlipidemia, thrombosis, apoplexy, cerebral infarction
Krill oil can reduce low density lipoprotein, LDL, triglyceride and cholesterol level in blood fast, promote that neutral or acid cholesterol is discharged automatically, suppress liver inner lipid and lipoprotein synthesis, adjusting blood lipid level, keep the quick flowing of blood, prevent hyperlipidemia and thrombosis from producing.Meanwhile, the omega-fatty acid in krill oil can also reduce the platelet of being crowded with cholesterol, and prevents the grumeleuse of energy occluding vascular from being formed.Unobstructed to maintenance cerebrovascular, prevent cerebrovascular from narrowing because of hyperlipidemia or blocking, minimizing apoplexy and cerebral infarction disease are sent out and are played an important role.
(3) hypertension
Krill oil focuses on the platelet in blood obvious resistancing action, and the expression of vascular adhesion molecule can be stoped, stimulate blood vessel endothelial cell activity, allow blood vessel be in relaxed state, thus can effectively improve because of vasospasm, distortion, the narrow hypertension caused.
Fish oil is the general designation of the whole oily substances in fish body, it comprises body oil, liver oil and cerebrol, main fish oil is a kind of oils and fats extracted from greasiness Fish, be rich in polyunsaturated fatty acid (DHA and EPA), there is the health benefits such as antiinflammatory, adjusting blood lipid, can prevention of arterial sclerosis and thrombosis.
Fish oil mainly has following effect:
(1) adjusting blood lipid, prevents blood coagulation, prevention cerebral thrombosis, cerebral hemorrhage and apoplexy;
(2) reduce blood fat, cleaning thrombosis, improve memory.
EPA and DHA obtained from meals based on every day in the coastal resident of edible marine organisms comparatively inland resident for height.In general inland crowd, in body, unsaturated fatty acid content is lower.
Salvia Hispanica L. seed oil: Salvia Hispanica L. (ChiaSeed) has another name called strange refined son, Salvia Hispanica L. seed, formal name used at school salvia hispanica L (SalviaHispanicaL.), pennyroyal, original producton location is the area, North America such as Mexico south and Guatemala, the area desert band height above sea level less than 4000 feet can be grown, the Salvia Hispanica L. of the usual indication of people is the seed of this plant in fact---Salvia Hispanica L. seed.
It is rich in the abundantest food of fatty acid, and containing the Natural antioxidant.The edible history of Salvia Hispanica L. seed can trace back to B.C. 3500, is the safety food of U.S. FDA certification now, the bread adding ingredient of Ye Shi European Union legislative confirmation.
And above-mentioned three kinds of raw material phosphor shrimp sauces, fish oil, Salvia Hispanica L. seed are oily, the effect all containing a large amount of unsaturated fatty acids in its composition, and unsaturated fatty acid has many benefits to health, specific as follows:
(1) adjusting blood lipid
Hyperlipidemia causes the main cause of the diseases such as hypertension, arteriosclerosis, heart disease, cerebral thrombosis, apoplexy, and the main component EPA in fish oil and DHA, can reduce cholesterol harmful in blood and triglyceride; Effectively can control the concentration of human body blood fat; And the content improved the useful high density lipoprotein of human body.Maintaining low concentration blood lipid level to keeping fit, angiocardiopathy preventing, improving endocrine and all play a part key.
(2) thrombosis is cleared up
The bathypelagic fish oil of supplementing with diet can promote the metabolism of satisfied fatty acid in body, alleviate and eliminate Animal fat in food (mainly from fat meat, milk product etc.) to the harm of human body, prevent the sedimentation of fat in blood vessel wall, suppress atherosclerotic formation and development, strengthen elasticity and the toughness of blood vessel, reduce blood viscosity, promote the ability that erythrocyte takes oxygen.EPA in fish oil, prevents the function of PA, cohesion in addition, and therefore it can the formation of effectively anti-tampon, prevention of stroke.
(3) immunomodulating
Supplement EPA, DHA, can enhancing human body immunity power, improve the ability that self immune system defeats cancerous cell.The research of Japan finds that the DHA in fish oil can inducing cancer cell " suicide ".According to another interrelated data report, fish oil is very remarkable to effects such as prevention and prohibition breast carcinoma.The serial unsaturated fatty acid of ω-3 can in order to landman's body self immune system, and in Britain, the U.S. and some developed countries, bathypelagic fish oil is also used to adjuvant therapy of diabetes, psoriasis, rheumatoid arthritis and systemic lupus erythematosus (sle) disease.Bathypelagic fish oil also suffers from special efficacy to anaphylactic disease, limitation gastroenteritis and skin disease.
(4) safeguard that retina improves vision
DHA is amphiblestroid important component part, accounts for 40 ~ 50%.Supplement the retina cell of enough DHA to activation decline helpful, have therapeutical effect to the disease such as tired, senile dim eyesight, blurred vision, glaucoma, cataract that excess eye-using causes.DHA also can provide optic nerve desired nutritional composition, and prevents visual disorder.
(5) supplementing the brain brain-strengthening
DHA is that brain cell forms growth and the indispensable material base that moves.People has memory, function and thinking to depend on DHA to maintain and improves.Supplementary DHA can promote that brain cell reaches full growth, and delays intelligence and declines, forgetful and prevention Alzheimer (senile dementia) etc.
(6) improve arthritic symptom to ease the pain
The serial unsaturated fatty acid of ω-3 can be assisted and be formed lubricating fluid in articular cavity, and improve the ability of leukocytic anti-inflammation and sterilization in body, ameliorate osteoarthritis symptom, lubricating joint, eases the pain.
The present invention adopts krill oil, fish oil and Salvia Hispanica L. seed oil cooperatively interact, complement each other, wherein, ω-3 essential fatty acid eicosapentaenoic acid (EPA) and docosahexenoic acid (DHA) is all rich in krill oil and fish oil, and Salvia Hispanica L. seed oil generally acknowledges to be rich in the abundantest food of omega-fatty acid, and containing the Natural antioxidant, unsaturated fatty acid in three kinds of raw materials can help human body adjusting blood lipid, cleaning thrombosis, prevent blood coagulation, prevention cerebral thrombosis, cerebral hemorrhage and apoplexy, improve memory, body immunity can also be improved, safeguard retina, improve vision, simultaneously, also containing the Natural antioxidant in Salvia Hispanica L. seed oil, contribute to slow down aging, maintain the young state of body, thus further improve human immunity mechanism, maintain health.Above-mentioned three kinds of components complement each other, and mutually coordinate, and have given play to its respective effect separately, have also enable effect of the unsaturated fatty acid in three kinds of components give full play to and absorbed well by human body, improve drug effect.
In order to solve the problem, the embodiment of the invention also discloses a kind of preparation method of above-mentioned unsaturated fatty acid dietary supplement, comprising the following steps:
(1) glue preparation: gelatin part water soaking is made its imbibition, obtains expansion gelatin, is then heated to 70-80 DEG C by glycerol, expansion gelatin and remaining water mix homogeneously, stirs and makes it dissolve, obtain glue;
(2) pelleting: by krill oil, fish oil, the mixing of Salvia Hispanica L. seed oil, obtain mixed material, then mixed material and step (1) gained glue are carried out pelleting, obtained soft capsule, in described pelleting process, temperature is 22-24 DEG C, and relative humidity is 40-45%;
(3) shape: soft capsule obtained for step (2) is shaped, described in be fixed to temperature be 22-24 DEG C, relative humidity be the environment of 40-45% under dry 3-5 hour;
(4) dry: it is 26-28 DEG C that the soft capsule after step (3) being shaped is placed in temperature, and relative humidity is carry out drying under 30-40% environment, and drying time is 22-26h.
Optionally, also comprise in step (1) and glue is kept 70-80 DEG C, leave standstill 1-2h, removing offscum, then vacuumizing and defoaming.
Optionally, in step (1), after vacuumizing and defoaming, then filtered by glue, then stand for standby use under 55-65 DEG C of condition, described filtration adopts 80-120 mesh sieve.
Optionally, the soft capsule after step (3) being shaped adopts ethanol to carry out cleaning to remove the oil stain on soft capsule shell before step (4) is dry.
Optionally, step (4) dried soft capsule is selected, rejects underproof soft capsule, retain qualified soft capsule.
Preparation method provided by the present invention, it is simple to operate, convenient, safe, efficient, energy-conservation, be suitable for industrialization promotion.
Detailed description of the invention
Hereinafter will describe the present invention in detail in conjunction with the embodiments.It should be noted that, when not conflicting, the embodiment in the present invention and the feature in embodiment can combine mutually.
Embodiment 1
Present embodiments provide a kind of unsaturated fatty acid dietary supplement, be prepared from by following raw material by weight: krill oil 15 parts, 55 parts, fish oil, Salvia Hispanica L. seed oil 10 parts, 20 parts, gelatin, glycerol 8 parts, purified water 20 parts, described dietary supplement dosage form is soft capsule.
The preparation method of above-mentioned unsaturated fatty acid dietary supplement is specific as follows:
(1) glue preparation: gelatin partial purification water soaking is made its imbibition, must be expanded gelatin, then glycerol, expansion gelatin and remaining purified water mix homogeneously are heated to 75 DEG C, stir and make it dissolve, after expansion gelatin and glycerol dissolve completely, keep 75 DEG C of constant temperature, leave standstill 1.5h, removing offscum, then vacuumizing and defoaming, glue is obtained, stand for standby use under gained glue 60 DEG C of conditions after 100 mesh sieves filter;
(2) pelleting: by krill oil, fish oil, the mixing of Salvia Hispanica L. seed oil, obtain mixed material, then mixed material and step (1) gained glue are carried out pelleting, obtained soft capsule, in described pelleting process, temperature is 22 DEG C, and relative humidity is 42%;
(3) shape: by soft capsule obtained for step (2) temperature be 22 DEG C, relative humidity is dry under being the condition of 42% within 4 hours, shapes;
(4) ball is washed: the ethanol being 95% by the soft capsule employing mass fraction after step (3) sizing carries out cleaning to remove the oil stain on soft capsule shell;
(5) dry: it is 27 DEG C that the soft capsule after step (4) being cleaned is placed in temperature, and relative humidity is carry out drying under 35% environment, and drying time is 24h;
(6) step (5) dried soft capsule is selected, reject underproof soft capsule, retain qualified soft capsule, then qualified soft capsule is packed, checks, put in storage.
Embodiment 2
Present embodiments provide a kind of unsaturated fatty acid dietary supplement, be prepared from by following raw material by weight: krill oil 5 parts, 100 parts, fish oil, Salvia Hispanica L. seed oil 5 parts, 25 parts, gelatin, glycerol 10 parts, purified water 25 parts, described dietary supplement dosage form is soft capsule.
The preparation method of above-mentioned unsaturated fatty acid dietary supplement is specific as follows:
(1) glue preparation: gelatin partial purification water soaking is made its imbibition, must be expanded gelatin, then glycerol, expansion gelatin and remaining purified water mix homogeneously are heated to 80 DEG C, stir and make it dissolve, after expansion gelatin and glycerol dissolve completely, keep 80 DEG C of constant temperature, leave standstill 1h, removing offscum, then vacuumizing and defoaming, glue is obtained, stand for standby use under gained glue 65 DEG C of conditions after 80 mesh sieves filter;
(2) pelleting: by krill oil, fish oil, the mixing of Salvia Hispanica L. seed oil, obtain mixed material, then mixed material and step (1) gained glue are carried out pelleting, obtained soft capsule, in described pelleting process, temperature is 23 DEG C, and relative humidity is 45%;
(3) shape: soft capsule step (2) obtained is 23 DEG C in temperature, relative humidity is dry under 45% condition sizing for 5 hours;
(4) ball is washed: the ethanol being 95% by the soft capsule employing mass fraction after step (3) sizing carries out cleaning to remove the oil stain on soft capsule shell;
(5) dry: it is 28 DEG C that the soft capsule after step (4) being cleaned is placed in temperature, and relative humidity is carry out drying under 30% environment, and drying time is 26h;
(6) step (5) dried soft capsule is selected, reject underproof soft capsule, retain qualified soft capsule, then qualified soft capsule is packed, checks, put in storage.
Embodiment 3
Present embodiments provide a kind of unsaturated fatty acid dietary supplement, be prepared from by following raw material by weight: krill oil 30 parts, 30 parts, fish oil, Salvia Hispanica L. seed oil 20 parts, 23 parts, gelatin, glycerol 12 parts, purified water 23 parts, described dietary supplement dosage form is soft capsule.
The preparation method of above-mentioned unsaturated fatty acid dietary supplement is specific as follows:
(1) glue preparation: gelatin partial purification water soaking is made its imbibition, must be expanded gelatin, then glycerol, expansion gelatin and remaining purified water mix homogeneously are heated to 70 DEG C, stir and make it dissolve, after expansion gelatin and glycerol dissolve completely, keep 70 DEG C of constant temperature, leave standstill 2h, removing offscum, then vacuumizing and defoaming, glue is obtained, stand for standby use under gained glue 55 DEG C of conditions after 120 mesh sieves filter;
(2) pelleting: by krill oil, fish oil, the mixing of Salvia Hispanica L. seed oil, obtain mixed material, then mixed material and step (1) gained glue are carried out pelleting, obtained soft capsule, in described pelleting process, temperature is 24 DEG C, and relative humidity is 40%;
(3) shape: soft capsule step (2) obtained is 24 DEG C in temperature, relative humidity is dry under the condition of 40% sizing for 3 hours;
(4) ball is washed: the ethanol being 95% by the soft capsule employing mass fraction after step (3) sizing carries out cleaning to remove the oil stain on soft capsule shell;
(5) dry: it is 26 DEG C that the soft capsule after step (4) being cleaned is placed in temperature, and relative humidity is carry out drying under 40% environment, and drying time is 22h;
(6) step (5) dried soft capsule is selected, reject underproof soft capsule, retain qualified soft capsule, then qualified soft capsule is packed, checks, put in storage.
Testing inspection is carried out to embodiment of the present invention gained sample below
1, safety experiment:
Materials and methods
Sample: adopt the embodiment of the present invention 1 gained sample, specification 1.0g/ grain.The oral recommendation consumption of people is everyone (adult) every day 2, and adult's body weight is pressed 60kg and calculated, and amounting to dosage is 33.3mg/kg.BW.
Experimental animal and environment: the healthy Kunming mouse of SPF level, bred by Sichuan University's West China Experimental Animal Center.Animal Lab. is barrier system, laboratory animal room temperature: 21 ~ 23 DEG C, relative humidity: 65 ~ 75%.
Chmice acute Oral toxicity is tested: adopt maximum resistance test method, select the Kunming mouse 20 of body weight 18 ~ 22g, male and female half and half.Before test, animal fasting 16 hours, does not limit drinking-water.Take 50.0g sample, add pure water to 100mL, mix, be made into 500mg/mL strength solution, then give animal gavage 2 times (interval 6h), each gavage amount is 0.4mL/20g.BW, and total dosage is 20000mg/kg.BW.Observe, record the poisoning manifestations of animal after gavage.Weigh weekly once, observe two time-of-weeks, off-test is dissected animal and is carried out gross examination of skeletal muscle.By the acute toxicity of toxicity grading standard evaluation tested material.
Table 1. sample is to the acute toxicity tests of mice
Result: as seen from Table 1, after giving mouse stomach with the sample of 20000mg/kg.BW dosage, growth of animal is good, has no body weight and receives impact.Test mice has been showed no poisoning symptom, observes 14 days without animal dead.Animal, gross examination of skeletal muscle are dissected in off-test, and the main organs such as liver,kidney,spleen, the heart, lung, stomach, intestinal are showed no obvious abnormalities change.Result shows, the acute oral toxicity dosage of this sample to mice is greater than 20000mg/kg.BW, and acute oral toxicity belongs to nontoxic.Its result of the test of other embodiments of the invention gained sample is identical with embodiment 1.
2, functional experiment:
Materials and methods
Sample: adopt the embodiment of the present invention 1 gained sample, specification 1.0g/ grain.The oral recommendation consumption of people is everyone (adult) every day 2, and adult's body weight is pressed 60kg and calculated, and amounting to dosage is 33.3mg/kg.BW.
Experimental animal and raising
SPF level male SD rat 36, body weight 150-200g, is provided by Sichuan Academy of Medical Sciences's Animal Experimental Study center.Animal feeding is in barrier level (IVC) Animal House.In whole experimentation, animal freely ingests and drinks water, room temperature 19-22 DEG C, relative humidity 50%-70%.
Feedstuff:
A) normal feedstuff: Sichuan University's Experimental Animal Center provides;
B) high lipid food (%): normal feedstuff 78.8, Adeps Sus domestica 10, yolk powder 10, cholesterol 1, cholate 0.2.
Key instrument and reagent
Olympus400 type automatic clinical chemistry analyzer (Japan), Australian Olympus company clinical biochemical reagent.
Experimental technique
Rat is with normal feedstuff adaptability feed after seven days, get tail hematometry basis TC, TG and HDL-C level, according to TC level, following four groups are divided into: 166.5mg/kg.BW, 333mg/kg.BW, 666mg/kg.BW (being equivalent to 5,10,20 times of human intaking amount 33.3mg/kg.BW) and matched group by random packet principle, every treated animal 9, four treated animals all use high lipid food feed.Experimental group is with the sample gavage of corresponding dosage, and matched group is with same volume edible vegetable oil gavage, and gavage amount is 10ml/kg.BW, and once a day, continuous gavage 30 days, weighs weekly and adjust gavage amount by body weight.Experiment terminates fasting 16 hours, gets blood measure TC, TG and HDL-C from rat femoral.
Experimental result
(1) sample is on the impact of rat body weight
As shown in table 2, the body weight of sample three dosage group rats and weightening finish compared with matched group, difference that there are no significant (P > 0.05).Show that tested material has no adverse effects to rat body weight.
Table 2. sample must affect rat body weight
(2) sample is on the impact of rat fat
As shown in table 3, before TC, TG of matched group is significantly higher than test during off-test, show hyperlipidemia model success.At the end of experiment, the TC of the basic, normal, high dosage group of sample is significantly lower than matched group (P < 0.05); The TG of basic, normal, high dosage group is significantly lower than matched group (P < 0.05).
Table 3. sample is on the impact of Serum TC, TG, HDL-C
# compares with before test, P < 0.01; * compare with matched group, P < 0.05
Conclusion: auxiliary lipid-lowering function animal test results shows, this tested material has no adverse effects to rat body weight; Before TC, TG of matched group is significantly higher than test at the end of experiment, show hyperlipidemia model success; During off-test, the basic, normal, high dosage group of tested material obtains TC significantly lower than matched group (P < 0.05); The TG of basic, normal, high dosage group is significantly lower than matched group (P < 0.05).By evaluation criterion, the embodiment of the present invention 1 has auxiliary lipid-lowering function.Coming to the same thing of its experimental result of other embodiments of the invention gained sample and embodiment 1.
3, human experiment report:
(1) experimenter selects
Study subject: by the principle of voluntariness select 18-65 year, hyperlipidemia person.
The person's of including in standard: simple dyslipidemia crowd, usual diet.Blood sampling 2 times in half a year, twice serum total cholesterol (TC) all >=5.2mmol/L and serum triglycerides (TG) >=1.65mmol/L, can test-meal observation be carried out.
Eliminator's standard:
A, age under-18s or over-65s person, gestation or women breast-feeding their children, those who are allergic to the health care products;
B, be associated with the serious diseases such as heart kidney and hemopoietic system, psychotic;
C, take the article relevant with tested function in a short time, have influence on the judgement person to result;
D, do not meet inclusive criteria, not by regulation tested material, cannot judge effect or data not umbra ring effect or safety judgement person;
(2) EXPERIMENTAL DESIGN and grouping require: 120 routine experimenters are divided into test-meal group and blank group at random, adopt before and after self and contrast form with between group.Tested period keeps life on ordinary days and dietary habit.Get the every biochemical indicator of hematometry on an empty stomach.
(3) taking dose and the time: test-meal group dose, each 1, every day 2 times, continuous 90 days, the embodiment of the present invention 1 gained sample is adopted.
(4) instrument and reagent: F-820 type blood counting instrument, (Japan produces) MIDIRON layer ten analyser (Germany produces), RA1000 automatic clinical chemistry analyzer (U.S.'s product), biochemical reagents box is all provided by Zhong Sheng company.
(5) observation index
Safety observations
Ordinary circumstance:
Detailed medical history-taking, understands the situations such as experimenter's spirit, diet, sleep, defecation, heart rate, blood pressure, observes main clinic symptoms: tired, uncomfortable in chest, dizzy, irritated etc.Before and after test-meal, add up integrated value by symptom weight (serious symptom 3 points, moderate 2 points, mild 1 point), and with regard to its cardinal symptom improve (each symptom improve 2 points effective, improve 1 point effectively), calculate improvement rate.
Blood and urine and stool routine examination:
Red blood cell count(RBC), hemoglobin, numeration of leukocyte, routine urinalysis, just routine examination.
Biochemical Indexes:
Serum albumin ALB, albumin TP, darling renal function (glutamic oxaloacetic transaminase, GOT AST, glutamate pyruvate transaminase ALT, carbamide UREA, inosine CRE), blood glucose GLU.
Abdominal B type ultrasonography, electrocardiogram, x-ray fluoroscopy of chest.
Untoward reaction is observed.
(6) efficiency index:
Serum total cholesterol level and reduction percentage rate, triglyceride levels and reduction percentage rate, High-density Lipoprotein-cholesterol ascensional range.
(7) effect criterion:
A, effectively:
Cholesterol decline > 10%, triglyceride decline > 15%, HDL-C rising > 0.104mmol/L.Serum total cholesterol, triglyceride, test-meal group self compares and between matched group group, comparing difference has significance, and HDL-C is not significantly lower than matched group.
B, invalid:
Do not reach above standard person.
(8) experimental result:
General status:
Observe hyperlipidemia experimenter 120 example altogether, effective case 100 example, test-meal group male 12 example, women 38 example, maximum 65 years old, average 57.28 ± 6.78 years old, average course of disease 5.09 ± 4.00 years.Blank group male 17 example, women 33 example, minimum 38 years old of age, maximum 65 years old, average 57.44 ± 6.14 years old, average course of disease 5.17 ± 4.26 years.Before and after experimenter's test-meal, the symptom such as spirit, sleep, diet, defecation is without obvious change.
Table 4. is observed front ordinary circumstance and is compared (X ± SD)
Heart rate (beat/min), blood pressure (mmHg) change before and after table 5. test-meal
Cholesterol changes:
Cholesterol change unit before and after table 6. test-meal: (mmol/L)
| Number of cases | Before test-meal | After test-meal | Difference | Effective percentage % | |
| Test-meal group | 50 | 6.47±0.83 | 5.76±0.99 | 0.72±1.24** | 62 (31 examples) |
| Matched group | 50 | 6.61±1.10 | 6.54±1.31 | 0.06±0.99# | 20 (10 examples) |
Self compare between * * P < 0.01 group and compare #P < 0.05
The change of triglyceride:
Triglyceride change unit before and after table 7. test-meal: (mmol/L)
| Number of cases | Before test-meal | After test-meal | Difference | Effective percentage % | |
| Test-meal group | 50 | 2.93±0.99 | 2.18±0.98 | 0.75±0.98** | 74 (37 examples) |
| Matched group | 50 | 2.66±0.95 | 2.80±1.30 | -0.13±0.99# | 26 (13 examples) |
Self compare between * * P < 0.01 group and compare #P < 0.05
High density lipoprotein changes:
High density lipoprotein change unit before and after table 8. test-meal: (mmol/L)
| Number of cases | Before test-meal | After test-meal | Difference | Effective percentage % | |
| Test-meal group | 50 | 1.07±0.36 | 1.07±0.38 | 0.01±0.44 | 40 (20 examples) |
| Matched group | 50 | 1.16±0.46 | 1.11±0.42 | 0.06±0.40 | 28 (14 examples) |
Efficacy assessments:
Table 9. effect judges
| Number of cases | Effectively | Invalid | Total effective rate (%) |
| Test-meal group | 50 | 26 | 24 | 52.00％# |
| Matched group | 50 | 3 | 47 | 6.00％ |
#P < 0.05 is compared between group
Symptom improves situation:
Table 10. cardinal symptom improves situation
Symptom integral changes:
Table 11. symptom integral changes
| Group | Number of cases | Before test-meal | After test-meal |
| Test-meal group | 50 | 8.14±4.54 | 5.76±4.03** |
| Matched group | 50 | 7.32±4.90 | 5.82±4.42** |
**P＜0.01
Safety indexes detects:
Table 12. safety indexes detects
Before and after test-meal, indices is substantially in normal range.
Abdominal B type ultrasonography, electrocardiogram, x-ray fluoroscopy of chest, substantially in normal range.
Case depigmentation rate: test-meal group and matched group are respectively 60 examples, has 3 examples not take tested material, 7 routine detection data by regulation incomplete at the end of the test-meal of wherein test-meal group, matched group has 7 routine detection data incomplete, and 3 examples are dropped by the wayside.Test-meal group and matched group respectively have 10 examples to meet Subject Exclusion Criteria, and effective case often organizes 50 examples, and case depigmentation rate is 16.67%.
Conclusion:
On request, test-meal group takes sample, each 1 for a, 100 routine hyperlipidemia experimenters, every day 2 times, continuous 90 days.Matched group is blank group, and result test-meal group cholesterol on average declines 0.72 ± 1.24mmol/L, and triglyceride on average declines 0.75 ± 0.98mmol/L, high density lipoprotein on average raises 0.01 ± 0.44mmol/L, in 50 examples, effective 26 examples, total effective rate 52.00%.Blank group cholesterol on average declines 0.06 ± 0.99mmol/L, and triglyceride on average declines-0.13 ± 0.99mmol/L, and high density lipoprotein on average raises-0.06 ± 0.40mmol/L, in 50 examples, and effective 3 examples, total effective rate 6.00%.Test-meal group cholesterol and self compare and more all have significant difference between group.High density lipoprotein self compares and compares no significant difference between group.Interpret sample has the effect of auxiliary antilipemic.
B, sample are improved effect to the feeling of fatigue of hyperlipidemia experimenter, the symptom such as uncomfortable in chest, dizzy, irritated.
Before and after c, sample test-meal, the Testing index such as hemoglobin, erythrocyte, leukocyte, total serum protein, albumin, glutamate pyruvate transaminase, glutamic oxaloacetic transaminase, GOT, inosine, carbamide, blood glucose, routine urinalysis, just routine, substantially in normal range, illustrate that this product has no adverse effects to experimenter is healthy.
Before and after d, examination trencherman test-meal, heart rate, blood pressure are in normal range.Abdominal B type ultrasonography, electrocardiogram, x-ray fluoroscopy of chest, substantially in normal range.
After e, sample test-meal, have no irritated and other untoward reaction.
Adopt other embodiments of the invention to test, its acquired results is identical with embodiment 1.
It should be noted that, for aforesaid embodiment of the method, in order to simple description, therefore it is all expressed as a series of combination of actions, but those skilled in the art should know, the present invention is not by the restriction of described sequence of movement, because according to the present invention, some step can adopt other orders or carry out simultaneously.Secondly, those skilled in the art also should know, the embodiment described in description all belongs to preferred embodiment, and involved action might not be essential to the invention.
Last it is noted that above embodiment is only in order to illustrate technical scheme of the present invention, be not intended to limit; Although with reference to previous embodiment to invention has been detailed description, those of ordinary skill in the art is to be understood that: it still can be modified to the technical scheme described in foregoing embodiments, or carries out equivalent replacement to wherein portion of techniques feature; And these amendments or replacement, do not make the essence of appropriate technical solution depart from the spirit and scope of various embodiments of the present invention technical scheme.
Claims (7)
1. a unsaturated fatty acid dietary supplement, is characterized in that, is prepared from primarily of following raw material: krill oil 5 ~ 30 parts, 30 ~ 100 parts, fish oil, Salvia Hispanica L. seed oil 5 ~ 20 parts.
2. unsaturated fatty acid dietary supplement according to claim 1, is characterized in that, described dietary supplement dosage form is soft capsule.
3. unsaturated fatty acid dietary supplement according to claim 2, is characterized in that, also comprise gelatin 20-25 and divide, glycerol 8-12 divides, and water 20-25 divides.。
4. a preparation method for unsaturated fatty acid dietary supplement as claimed in claim 2 or claim 3, is characterized in that, comprise the following steps:
(1) glue preparation: gelatin part water soaking is made its imbibition, obtains expansion gelatin, is then heated to 70-80 DEG C by glycerol, expansion gelatin and remaining water mix homogeneously, stirs and makes it dissolve, obtain glue;
(2) pelleting: by krill oil, fish oil, the mixing of Salvia Hispanica L. seed oil, obtain mixed material, then mixed material and step (1) gained glue are carried out pelleting, obtained soft capsule, in described pelleting process, temperature is 22-24 DEG C, and relative humidity is 40-45%;
(3) shape: soft capsule obtained for step (2) is shaped, described in be fixed to temperature be 22-24 DEG C, relative humidity be the environment of 40-45% under dry 3-5 hour;
(4) dry: it is 26-28 DEG C that the soft capsule after step (3) being shaped is placed in temperature, and relative humidity is carry out drying under 30-40% environment, and drying time is 22-26h.
5. the preparation method of unsaturated fatty acid dietary supplement according to claim 4, is characterized in that, also comprises glue is kept 70-80 DEG C in step (1), leaves standstill 1-2h, removing offscum, then vacuumizing and defoaming.
6. the preparation method of unsaturated fatty acid dietary supplement according to claim 5, is characterized in that, in step (1), after vacuumizing and defoaming, filtered by glue, then stand for standby use under 55-65 DEG C of condition, described filtration adopts 80-120 mesh sieve again.
7. the preparation method of unsaturated fatty acid dietary supplement according to claim 4, it is characterized in that, the soft capsule after step (3) being shaped adopts ethanol to carry out cleaning to remove the oil stain on soft capsule shell before step (4) is dry.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510873194.0A CN105412227A (en) | 2015-12-02 | 2015-12-02 | Unsaturated fatty acid dietary supplement and preparing method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510873194.0A CN105412227A (en) | 2015-12-02 | 2015-12-02 | Unsaturated fatty acid dietary supplement and preparing method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105412227A true CN105412227A (en) | 2016-03-23 |
Family
ID=55491076
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510873194.0A Pending CN105412227A (en) | 2015-12-02 | 2015-12-02 | Unsaturated fatty acid dietary supplement and preparing method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105412227A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107372861A (en) * | 2017-08-24 | 2017-11-24 | 北京斯利安药业有限公司 | A kind of composition and its application in the product for improving hyperlipemia is prepared |
| CN108936632A (en) * | 2018-08-08 | 2018-12-07 | 深圳极醇健康产业股份有限公司 | A kind of krill fat capsule and preparation method thereof |
| CN111436611A (en) * | 2020-04-27 | 2020-07-24 | 新绎健康管理有限公司 | Composition containing complex unsaturated fatty acid |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1898370A (en) * | 2003-12-22 | 2007-01-17 | 湧永制药株式会社 | Fat composition |
| CN101534807A (en) * | 2006-07-14 | 2009-09-16 | 纳多制药股份公司 | Pharmaceutical and nutraceutical products comprising vitamin k2 |
| CN103687603A (en) * | 2011-06-29 | 2014-03-26 | 日本水产株式会社 | Method for alleviating fear memory |
| CN104106793A (en) * | 2013-04-18 | 2014-10-22 | 宁波大学 | Food and preparation method thereof |
| CN104126666A (en) * | 2014-03-26 | 2014-11-05 | 辽宁省大连海洋渔业集团公司 | Blended milk containing antarctic krill oil |
-
2015
- 2015-12-02 CN CN201510873194.0A patent/CN105412227A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1898370A (en) * | 2003-12-22 | 2007-01-17 | 湧永制药株式会社 | Fat composition |
| CN101534807A (en) * | 2006-07-14 | 2009-09-16 | 纳多制药股份公司 | Pharmaceutical and nutraceutical products comprising vitamin k2 |
| CN103687603A (en) * | 2011-06-29 | 2014-03-26 | 日本水产株式会社 | Method for alleviating fear memory |
| CN104106793A (en) * | 2013-04-18 | 2014-10-22 | 宁波大学 | Food and preparation method thereof |
| CN104126666A (en) * | 2014-03-26 | 2014-11-05 | 辽宁省大连海洋渔业集团公司 | Blended milk containing antarctic krill oil |
Non-Patent Citations (3)
| Title |
|---|
| 胡忠红等: "芡欧鼠尾草脂肪酸成分分析", 《中国粮油学报》 * |
| 荣旭等: "奇亚籽营养成分分析与评价", 《中国油脂》 * |
| 马云芳等: "奇亚籽的营养成分、健康功效和在食品工业中的应用", 《食品工业》 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107372861A (en) * | 2017-08-24 | 2017-11-24 | 北京斯利安药业有限公司 | A kind of composition and its application in the product for improving hyperlipemia is prepared |
| CN107372861B (en) * | 2017-08-24 | 2021-04-13 | 北京斯利安药业有限公司 | Composition and application thereof in preparation of product for improving hyperlipidemia |
| CN108936632A (en) * | 2018-08-08 | 2018-12-07 | 深圳极醇健康产业股份有限公司 | A kind of krill fat capsule and preparation method thereof |
| CN111436611A (en) * | 2020-04-27 | 2020-07-24 | 新绎健康管理有限公司 | Composition containing complex unsaturated fatty acid |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100542411C (en) | A kind of nutrition balanced mixed oil and production method thereof that contains omega-3 polyunsaturated fatty acids | |
| JP4540672B2 (en) | A composition containing an ingredient derived from salvia sclare seed as an active ingredient | |
| CN104719510A (en) | Pregnant woman and infant nutritional tea oil containing DHA and AA | |
| CN105595323A (en) | Phosphatide-unsaturated fatty acid compound health product and preparation method thereof | |
| CN104256610B (en) | A kind of health composition of auxiliary antilipemic and soft capsule | |
| CN105412227A (en) | Unsaturated fatty acid dietary supplement and preparing method thereof | |
| CN107441217B (en) | Oral emulsion rich in alpha-linolenic acid and preparation method thereof | |
| CN1579180A (en) | Mixed safflower oil | |
| CN101849585A (en) | Functional nutrient plant blend oil and preparation method thereof | |
| CN107373260A (en) | A kind of compound antilipemic healthy drinks and preparation method thereof | |
| CN102106534A (en) | Composition for assisting in lowering blood fat and preparation method thereof | |
| CN106418542A (en) | Health-care product having function of regulating blood lipids and preparation method thereof | |
| WO2012095749A1 (en) | Removal of monoglycerides from fatty acid concentrates | |
| CN102090486B (en) | Method for preparing nutrient linseed oil tea | |
| CN107308358A (en) | A kind of statin and the aliphatic acid of Omega 3 and vitamin complex composition | |
| CN105995980A (en) | Composition with weight management function and preparation method thereof | |
| CN107837298A (en) | A kind of sea-buckthorn oil health care product | |
| CN107372861B (en) | Composition and application thereof in preparation of product for improving hyperlipidemia | |
| CN105707568A (en) | Alpha-linolenic acid soft capsule with function of auxiliarily lowering blood lipids and preparation method thereof | |
| CN105192101A (en) | Nutritional formula oil | |
| CN108902357A (en) | A kind of preparation method of reducing blood lipid tea oil | |
| CN110122866A (en) | A kind of the special medicine purposes food and preparation method of chronic kidney disease angiosteosis | |
| CN100382797C (en) | Confected product containing lutein and/or carotene linolenic acid, and its preparation method | |
| CN1383887A (en) | Antisenility medicine composition and its prepn | |
| CN1568958B (en) | Unsaturated fatty acid formula products with high content of alpha and gamma linolenic acid and preparation method threreof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20160323 |